1stOncology™: Cancer Intelligence Service – Page 79 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

On April 6, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, reported the publication of two abstracts that will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The Company will present previously undisclosed data demonstrating the expanding potential of its Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies. Both presentations will occur on April 21, 2026 in the session Radiopharmaceutical Platforms for Theranostic Precision Oncology.

Sandesh Seth, Actinium’s Chairman and CEO, said, "These new data further validate the strength and versatility of our Ac-225 radiotherapy platform. ATNM-400 continues to show compelling pan-tumor activity, including activity in tumors resistant to current targeted therapies, supporting its potential as a first-in-class asset in large solid tumor indications. In parallel, Actimab-A’s newly identified mechanism of transcriptional reprogramming provides important insight into its mutation-agnostic activity and ability to enhance standard-of-care therapies. Together, these findings reinforce our strategy to build a differentiated pipeline with multiple value-driving opportunities."

ATNM-400 AACR (Free AACR Whitepaper) 2026 Presentation Details

Poster Number: 5824

Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology

Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #18

Actimab-A AACR (Free AACR Whitepaper) 2026 Presentation Details

Poster Number: 5827

Session: Radiopharmaceutical Platforms for Theranostic Precision Oncology

Date & Time: April 21, 2026 – 2:00 PM – 5:00 PM PT | Poster Section 16, Board #21

(Press release, Actinium Pharmaceuticals, APR 6, 2026, View Source [SID1234664178])

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On April 6, 2026 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On March 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

(Press release, Abeona Therapeutics, APR 6, 2026, View Source [SID1234664177])

Entry into a Material Definitive Agreement

On April 3, 2026 GT Biopharma, Inc., a Delaware corporation (the "Company"), reported to have entered into an Investigator Initiated Clinical Trial Agreement (the "Agreement") with the Regents of the University of Minnesota (the "University"), pursuant to which, the University shall sponsor an Investigational New Drug ("IND") application for IND 169118 GTB-5550 (the "Research Program") and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, "GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE), in Select Advanced Solid Tumors That Failed Prior Therapy," designed by University (the "Study"). The Research Program is being conducted for clinical research use. The budget for the Study, including without limitations, funding and resources, provides for up to approximately $3.8 million over the course of three years borne by the Company. The University and the Company will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon thirty days’ written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty days.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference into this Item 1.01.

(Filing, GT Biopharma, APR 3, 2026, View Source [SID1234664207])

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

On April 3, 2026 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, reported that data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, evaluating agent-797, MiNK’s allo-iNKT cell therapy, in combination with botensilimab (BOT) and balstilimab (BAL), will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA.

The study evaluates this multi-mechanistic immunotherapy regimen in patients with PD-1 refractory gastroesophageal cancer (GEC), an area of high unmet need where resistance to checkpoint inhibition remains a significant clinical challenge.

"This study represents one of the first clinical evaluations of an iNKT cell therapy combined with dual checkpoint modulation in gastroesophageal cancer and marks an important step in understanding how to re-engage the immune system in patients who have progressed on prior checkpoint therapy," said Jennifer Buell, Ph.D., President and CEO of MiNK Therapeutics.

"These data build on the immune-modulating findings we reported last year and extend them into the clinical setting. agenT-797 is designed to bridge innate and adaptive immunity as an immune orchestrator, with the potential to reprogram the tumor microenvironment and restore immune responsiveness. We believe these data will provide important insights into how immune reprogramming and treatment sequencing can drive more durable outcomes in refractory cancers and inform the next generation of combination strategies."

Presentation Details:

Abstract Title: A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC)

Presenter: Samuel L. Cytyrn, MD; Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center

Session Name: Phase II and Phase III Clinical Trials

Date/Time: April 20, 2026 | 2:00–5:00 PM PT; 5:00-8:00 PM EDT

Poster Section: 52

Abstract No.: CT166

(Press release, MiNK Therapeutics, APR 3, 2026, View Source [SID1234664173])

Innate Pharma to Participate in the Kempen Life Sciences Conference

On April 3, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, reported that members of its executive team will participate in one-on-one investor meetings at the following conference:

Kempen Life Sciences Conference

Dates: April 15 –16, 2026
Location: Amsterdam, Netherlands

(Press release, Innate Pharma, APR 3, 2026, View Source [SID1234664172])